Allogene Therapeutics (ALLO) Enterprise Value (2018 - 2026)

Allogene Therapeutics has disclosed Enterprise Value across 9 years of filings, most recently posting -$266.9 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$266.9 million, up 3.21% year-over-year; the trailing twelve-month figure through Mar 2026 was -$266.9 million (up 3.21% YoY), and the FY2025 annual result was -$250.2 million, up 14.45% from the prior year.
• Enterprise Value came in at -$266.9 million for Q1 2026 at Allogene Therapeutics, down from -$250.2 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$246.0 million in Q3 2025 to a low of -$552.2 million in Q3 2022.
• The 5-year median for Enterprise Value is -$435.5 million (2024), against an average of -$385.1 million.
• Across the five-year window, Enterprise Value dropped 16.84% in 2022 and surged 37.37% in 2024, its largest moves.
• Allogene Therapeutics' Enterprise Value stood at -$467.2 million in 2022, then increased by 3.96% to -$448.7 million in 2023, then jumped by 34.82% to -$292.5 million in 2024, then gained by 14.45% to -$250.2 million in 2025, then retreated by 6.66% to -$266.9 million in 2026.
• The last three Enterprise Value figures came in at -$266.9 million (Q1 2026), -$250.2 million (Q4 2025), and -$246.0 million (Q3 2025), per Business Quant data.